Analytica (ASX:ALT) Shares end Week on a High following Positive PeriCoach® Trial Results

  • November 21, 2020 01:41 PM AEDT
  • Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1706 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

Analytica (ASX:ALT) Shares end Week on a High following Positive PeriCoach® Trial Results

Summary

  • Medical device company Analytica Limited, on Friday, announced that PeriCoach® demonstrated non-inferiority to in-clinic pelvic floor physical therapy.
  • The trial results published in the prestigious Journal of Female Pelvic Medicine & Reconstructive Surgery.
  • The trial was designed for evaluating if home biofeedback is non-inferior to standard of care supervised PFPT for treating stress urinary incontinence.
26th feb webinar mtf mobile

ASX-listed medical device company Analytica Limited’s (ASX:ALT) shares had a strong end to the week after the release of favourable clinical trials results for its PeriCoach® therapy intervention. On 20 November 2020, ALT share price closed at A$0.003, up by an impressive 50%. The Company has a market capitalisation of almost A$7.03 million.

PeriCoach demonstrated non-inferiority to treat Stress Urinary Incontinence (SUI) to traditional supervised pelvic floor physical therapy.

Let us discuss the trial in detail-

About Analytica Limited

Brisbane-headquartered ASX-listed company Analytica Limited is engaged in designing, developing and commercialising Class I and Class II medical devices. The Company’s lead product, PeriCoach® System, is an e-health treatment system for Stress Urinary Incontinence patients.

PeriCoach has received TGA approval in Australia and also has a CE mark and FDA 510(k) clearance. The system has regulatory clearance in Australia for Pelvic Organ Prolapse treatment.

Primary outcome met in PeriCoach trial

On 20 November 2020, the medical devices company announced the publication of results from a clinical trial for PeriCoach from The University of New Mexico in an esteemed Journal of Female Pelvic Medicine & Reconstructive Surgery. The trial results demonstrated PeriCoach non-inferiority to in-clinic pelvic floor physical therapy.

The primary outcome measurement was met, with the biofeedback group using PeriCoach demonstrating non-inferiority to PFPT based on the quality of life score as measured by the International Consultation on Incontinence Questionnaire short form (ICIQ-SF).

PeriCoach trial in brief

The clinical trial was a randomised single-centre study led by principal investigator Dr Lauren de Winter.

The study was designed to assess whether home biofeedback is non-inferior to standard of care supervised pelvic floor physical therapy (PFPT) for treating stress urinary incontinence (SUI) in women who wish for non-surgical therapy.

The trial included 48 participants and compared PeriCoach personal biofeedback device usage with PFPT. It was aimed to support the implementation of personal biofeedback devices to overcome the issues with patient distance as well as the ability to maintain clinician monitoring.

Chairman of Analytica Dr Michael Monsour commented-

Dr Monsour also added that Analytica had the ambitious objective of forming a system to provide a treatment which is at the same level as that of pelvic floor physiotherapy (PFPT). The publication of the study in an esteemed Journal validates that the Company has met its objective.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK